RARE - Ultragenyx Pharmaceutical Inc.

QQQ $ 454.82 $ -0.84 (-0.19 %)

DIA $ 398.57 $ 6.05 (1.59 %)

SPY $ 530.36 $ 4.76 (0.91 %)

TLT $ 91.26 $ 0.61 (0.68 %)

GLD $ 225.37 $ -1.27 (-0.59 %)

Previous Close

$ 40.14

Open

$ 39.61

Bid

$ 40.02 x 100

Ask

$ 40.45 x 100

Day's Range

$ 39.21 - $ 40.72

52 Week Range

$ 31.52 - $ 54.98

Volume

1,518,406

Average Volume

Market Cap

3.38B

Beta (5Y Monthly)

$ 0.98

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-02-2024	03-31-2024	10-Q
2	02-21-2024	12-31-2023	10-K
3	11-02-2023	09-30-2023	10-Q
4	08-03-2023	06-30-2023	10-Q
5	05-05-2023	03-31-2023	10-Q
6	02-17-2023	12-31-2022	10-K
7	11-03-2022	09-30-2022	10-Q
8	07-28-2022	06-30-2022	10-Q
9	05-05-2022	03-31-2022	10-Q
10	02-15-2022	12-31-2021	10-K
11	11-02-2021	09-30-2021	10-Q
12	08-03-2021	06-30-2021	10-Q
13	05-05-2021	03-31-2021	10-Q
14	02-12-2021	12-31-2020	10-K
15	10-27-2020	09-30-2020	10-Q
16	07-31-2020	06-30-2020	10-Q
17	05-07-2020	03-31-2020	10-Q
18	02-14-2020	12-31-2019	10-K
19	11-06-2019	09-30-2019	10-Q
20	08-02-2019	06-30-2019	10-Q
21	05-07-2019	03-31-2019	10-Q
22	02-20-2019	12-31-2018	10-K
23	11-06-2018	09-30-2018	10-Q
24	08-03-2018	06-30-2018	10-Q
25	05-08-2018	03-31-2018	10-Q
26	02-21-2018	12-31-2017	10-K
27	11-03-2017	09-30-2017	10-Q
28	07-28-2017	06-30-2017	10-Q
29	05-05-2017	03-31-2017	10-Q
30	02-17-2017	12-31-2016	10-K
31	11-08-2016	09-30-2016	10-Q
32	08-09-2016	06-30-2016	10-Q
33	05-10-2016	03-31-2016	10-Q
34	02-26-2016	12-31-2015	10-K
35	11-10-2015	09-30-2015	10-Q
36	08-14-2015	06-30-2015	10-Q
37	05-12-2015	03-31-2015	10-Q
38	03-27-2015	12-31-2014	10-K
39	11-10-2014	09-30-2014	10-Q
40	08-11-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Wedbush Maintains Neutral on Ultragenyx Ph...
05/31/2024 17:39:50

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and raises the price target fro...

B of A Securities Maintains Buy on Ultrage...
05/31/2024 17:01:19

B of A Securities analyst Tazeen Ahmad maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price tar...

Canaccord Genuity Maintains Buy on Ultrage...
05/31/2024 16:59:54

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price tar...

Cantor Fitzgerald Maintains Overweight on ...
05/31/2024 14:36:14

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the ...

Peeling Back The Layers: Exploring Ultrage...
05/31/2024 14:00:47

Stifel Maintains Buy on Ultragenyx Pharmac...
05/31/2024 13:28:05

Stifel analyst Dae Gon Ha maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $124...

Baird Maintains Outperform on Ultragenyx P...
05/31/2024 12:16:16

Baird analyst Joel Beatty maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Outperform and raises the price target fr...

Ultragenyx Announces Top-Line Results From...
05/30/2024 20:00:59

Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) wit...

ultragenyx-faces-lawsuit-over-alleged-unjust-use-of-henrietta-lacks-cells

Ultragenyx Faces Lawsuit Over Alleged Unju...
05/22/2024 16:27:00

The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken wit...

Canaccord Genuity Maintains Buy on Ultrage...
05/06/2024 17:35:29

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price tar...

Cantor Fitzgerald Reiterates Overweight on...
05/03/2024 15:14:43

Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and maintains ...

Wedbush Maintains Neutral on Ultragenyx Ph...
05/03/2024 13:33:02

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target fro...

Ultragenyx Pharmaceuticals shares are trad...
05/03/2024 10:52:02

Ultragenyx Pharmaceutical Sees FY24 Revenu...
05/02/2024 20:01:55

Ultragenyx Pharmaceutical Q1 2024 GAAP EPS...
05/02/2024 20:00:58

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(2.03) per share which missed the analyst consensus estim...

Ultragenyx Announces Completion Of Enrollm...
04/30/2024 12:11:05

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and ...

TD Cowen Maintains Buy on Ultragenyx Pharm...
04/24/2024 17:24:03

TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from ...

Forecasting The Future: 11 Analyst Project...
04/22/2024 12:00:56

RBC Capital Initiates Coverage On Ultragen...
04/22/2024 09:42:30

RBC Capital analyst Luca Issi initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Outperform rating and ann...

Wedbush Reiterates Neutral on Ultragenyx P...
04/17/2024 17:20:21

Wedbush analyst Laura Chico reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and maintains $48 price target.